Omada Health Inc

OMDA

Market cap $906M

Omada Health, Inc. (OMDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis , findings underscore the program's role in helping employers manage the complexity of today's weight loss medication market while delivering measurable, long-term value.1 The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,1 compared to 11.9% weight loss seen in real world evidence.2 Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,1 compared to published real world evidence.2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss1 – nearly twice the amount observed in the real world analysis.2 “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits.

SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, including a presentation on Wednesday, Jan. 14, at 9 a.m.

Omada Health remains a 'Buy' as Q3 results validated strong growth, with revenue up 50% y/y to $68 million and membership reaching 831,000. OMDA's new GLP-1 prescribing capability deepens client integration, enhances ROI, and strengthens competitive positioning in a complex medication landscape. Multi-condition adoption accelerated, with ~75% of new customers using multiple programs, driving operating leverage and reducing client churn risk for OMDA.

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events . A replay will also be available at the same link following the event.

Pune, India, Nov. 18, 2025 (GLOBE NEWSWIRE) -- QKS Group announced that it has named Omada a Technology Leader and Emerging Innovator in the analysis of the global SPARK MatrixTM: Identity Governance and Administration (IGA), Q4 2025. The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK MatrixTM. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.

Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.

Omada Health, Inc. ( OMDA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Allan Kells - Vice President of Investor Relations Sean Duffy - Co-Founder, CEO & Director Wei-Li Shao - President Steven Cook - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Craig Hettenbach - Morgan Stanley, Research Division Richard Close - Canaccord Genuity Corp., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Saket Kalia - Barclays Bank PLC, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Gene Mannheimer Presentation Operator Good day, and thank you for standing by. Welcome to the Omada Health Third Quarter 2025 Earnings Conference Call.

The headline numbers for Omada Health, Inc. (OMDA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.